gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Partner and localizer of BRCA2

This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Iris, Bach1, Atm, Chk2, p53
Papers on PALB2
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Campbell et al., Newcastle, Australia. In J Clin Oncol, Feb 2016
A significant excess of mutations was only observed for PALB2 (26 cases, four controls) and TP53 (five cases, zero controls), whereas no mutations were identified in STK11.
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Chen et al., Houston, United States. In Ann Oncol, Feb 2016
Pathogenic variants in 18 genes, recommended for return by The American College of Medical Genetics and Genomics, as well as PALB2, were considered actionable.
Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing.
Teo et al., Kuala Selangor, Malaysia. In Clin Genet, Feb 2016
UNASSIGNED: Although an association between protein-truncating variants and breast cancer risk has been established for 11 genes, only alterations in BRCA1, BRCA2, TP53 and PALB2 have been reported in Asian populations.
Inherited Mutations in Women With Ovarian Carcinoma.
Birrer et al., Providence, United States. In Jama Oncol, Jan 2016
Mutations in BRIP1 (n = 26), RAD51C (n = 11), RAD51D (n = 11), PALB2 (n = 12), and BARD1 (n = 4) were significantly more common in patients with OC than in the ESP or ExAC, present in 3.3%.
Genetic characterization of early onset ovarian carcinoma.
Swisher et al., Seattle, United States. In Gynecol Oncol, Jan 2016
We evaluated 11 genes associated with ovarian carcinoma (BARD1, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51D, and RAD51C) and additional candidate genes in DNA repair (ATM, BAP1, CHEK2, MRE11A, NBN, PTEN, TP53).
A mechanism for the suppression of homologous recombination in G1 cells.
Durocher et al., Toronto, Canada. In Nature, Jan 2016
Here we report that the cell cycle controls the interaction of BRCA1 with PALB2-BRCA2 to constrain BRCA2 function to the S/G2 phases in human cells.
Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Narod et al., Toronto, Canada. In Expert Rev Anticancer Ther, Nov 2015
After BRCA1/2, the prevalence of pathogenic mutations was highest in CHEK2 (1.3%), PALB2 (0.9%) and ATM (0.8%).
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
Klein et al., Baltimore, United States. In Nat Genet, Aug 2015
2), ATM, PALB2 (ref.
Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics.
Surrallés et al., Spain. In Curr Opin Genet Dev, Aug 2015
Monoallelic mutations in 6 FA associated genes (FANCD1, FANCJ, FANCM, FANCN, FANCO and FANCS) predispose to breast and ovarian cancer.
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
Polish Hereditary Breast Cancer Consortium et al., Szczecin, Poland. In Lancet Oncol, Jun 2015
BACKGROUND: Mutations in PALB2 predispose to breast cancer, but the effect on prognosis of carrying a PALB2 mutation has not been ascertained.
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Jasin et al., New York City, United States. In Cold Spring Harb Perspect Biol, Apr 2015
Other HR proteins, including PALB2 and RAD51 paralogs, have also been identified as tumor suppressors.
Whole genomes redefine the mutational landscape of pancreatic cancer.
Grimmond et al., Brisbane, Australia. In Nature, Mar 2015
Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency.
[Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].
Foretová et al., In Klin Onkol, 2014
Various pathogenic or potentially pathogenic (missense, predicted splice site, in-frame insertion/deletion) mutations were detected in ATM, BRIP1, CDH1, CHEK2, ERCC2, ERCC3, ERCC4, FANCA, MC1R, MEN1, MRE11A, MUTYH, PALB2, RAD51C, RET, SDHB, STK11.
Hereditary ovarian cancer: not only BRCA 1 and 2 genes.
Cortesi et al., Modena, Italy. In Biomed Res Int, 2014
Nevertheless, several other suppressor genes and oncogenes have been associated with hereditary ovarian cancers, including the mismatch repair (MMR) genes in Lynch syndrome, the tumor suppressor gene, TP53, in the Li-Fraumeni syndrome, and several other genes involved in the double-strand breaks repair system, such as CHEK2, RAD51, BRIP1, and PALB2.
Pancreatic Cancer Diagnostics and Treatment - Current State.
Ulrych et al., Praha, Czech Republic. In Prague Med Rep, 2014
BRCA2, PALB2) have been identified as significant and highly penetrative, but link between PDAC and these genes can be seen only in 10-20%.
Rare germline mutations in PALB2 and breast cancer risk: a population-based study.
Begg et al., Montréal, Canada. In Hum Mutat, 2012
rare PALB2 missense mutations strongly influence breast cancer risk
PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.
Xia et al., New Brunswick, United States. In Mol Cell Biol, 2012
PALB2 promotes NRF2 accumulation and function in the nucleus and lowers the cellular reactive oxygen species (ROS) level. In addition, PALB2 also regulates the rate of NRF2 export from the nucleus following induction
Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges.
Kroupis et al., Athens, Greece. In Clin Chem Lab Med, 2012
PALB2 emerges as the third breast cancer susceptibility gene
ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair.
Esashi et al., Oxford, United Kingdom. In Embo Rep, 2012
These results suggest that PALB2 chromatin association via ChAM facilitates PALB2 function in the cellular resistance to DNA damage.
Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains.
Jasin et al., New York City, United States. In Plos Genet, 2011
BRCA2 fusion peptide deleted for the DNA binding domain and active in homologous recombination is completely dependent on interaction with the PALB2 tumor suppressor for activity
share on facebooktweetadd +1mail to friends